A Pragmatic Trial of a Shared Decision-Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Study - Takeaways - MDSpire

A Practical Study on a Collaborative Decision-Making Approach to Enhance Medication Compliance and Health Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Investigation

  • By

  • Caroline Packee

  • Jay J. Patel

  • Jessica Kent

  • Betty Chewning

  • Sancia Ferguson

  • Patricia Tellez-Giron

  • David Gazeley

  • Christie M. Bartels

  • Shivani Garg

  • June 4, 2026

Share

  • 1

    Hydroxychloroquine (HCQ) is essential for treating systemic lupus erythematosus (SLE) but has an 83% discontinuation rate among patients.

  • 2

    Patients face challenges in treatment decision-making due to misalignment of goals, lack of support, and linguistic barriers.

  • 3

    Shared decision-making (SDM) tools like HCQ-SAFE can enhance communication between patients and clinicians, improving adherence.

  • 4

    The HCQ-SAFE tool was developed through collaboration with patients, clinicians, and health literacy experts to ensure cultural appropriateness.

  • 5

    A clinical trial is underway to evaluate the effectiveness of HCQ-SAFE in reducing decisional conflicts and improving medication adherence.

Original Source(s)

A Pragmatic Trial of a Shared Decision-Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Study

  • by Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez-Giron, David Gazeley, Christie M. Bartels, Shivani Garg

  • June 4, 2026

Related Content

In Vivo CAR T: A New Route to Treating Autoimmune Disease

How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments

Global research landscape and emerging trends of tertiary lymphoid structures in autoimmune diseases: a bibliometric analysis

The mirror of illness: identity, embodiment, and clinical care in systemic sclerosis